Showing results (141-150 of 331) with videos related to
Sort By:
Pageof 34
Nature Communications|January 12, 2026
RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistanceChi Yan, Weifeng Luo, Jinming Yang, et al.Journal for Immunotherapy of Cancer|June 20, 2020
Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and managementJarushka Naidoo, Joshua E Reuss, Karthik Suresh, et al.Medrxiv : the Preprint Server for Health Sciences|January 18, 2024
Pembrolizumab alters the tumor immune landscape in a patient with dMMR glioblastomaTodd Bartkowiak, Asa A Brockman, Bret C Mobley, et al.The Oncologist|March 2, 2019
Hematologic Complications of Immune Checkpoint InhibitorsElizabeth J Davis, Joe-Elie Salem, Arissa Young, et al.Cardiovascular Research|February 5, 2019
Cardiovascular toxicities associated with immune checkpoint inhibitorsJiun-Ruey Hu, Roberta Florido, Evan J Lipson, et al.British Journal of Cancer|August 23, 2022
Clinical and genomic correlates of imatinib response in melanomas with KIT alterationsSeungyeon Jung, Emma Armstrong, Alexander Z Wei, et al.Journal for Immunotherapy of Cancer|November 22, 2017
Smoldering myocarditis following immune checkpoint blockadeTimothy G Norwood, Brian C Westbrook, Douglas B Johnson, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 19, 2019
Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic MelanomaElizabeth J Davis, Matthew C Perez, Noura Ayoubi, et al.Frontiers in Immunology|April 4, 2025
Molecular analysis of immune checkpoint inhibitor associated erythema nodosum-like toxicityXiaopeng Sun, Margaret L Axelrod, Paula I Gonzalez-Ericsson, et al.Nature Communications|May 5, 2026
A retrospective pharmacovigilance analysis based on the FAERS database reveals sex-associated differences in toxicities of CAR T-cell therapyYuan Liu, Jingwen Yang, Madiha Iqbal, et al.Pageof 34